Our Services
Medical Information
Helpful Resources
Published on: 10/9/2026
Mild redness, swelling, warmth, itching, or soreness at an injection site is usually normal and typically fades within a few days, while a small firm lump can linger slightly longer. Warning signs that deserve prompt attention include spreading redness, streaking, pus or drainage, fever, severe or worsening pain, a hard hot area that expands after 48 hours, or hives, facial swelling, and breathing trouble, which may signal infection or allergic reaction. The timing, size, and progression of the reaction all matter when distinguishing an expected immune response from a complication, so several factors should be weighed before deciding whether to wait or seek care, and the important details are explained below.
Because a bruise, an abscess, cellulitis, and a harmless immune flare can look similar in the first 24 to 72 hours, a structured check of your specific symptoms is far more useful than comparing photos online. Take a free, instant symptom check to clarify what your reaction most likely is and what the right next step should be.
Last reviewed for medical accuracy: 10/08/2026
Getting a shot—whether it’s a vaccine, antibiotic, vitamin B12, or other injectable—often comes with some soreness or redness at the site. Most of the time, these reactions are mild and clear up on their own. However, it can be tricky to know when a reaction is just part of the normal healing process and when it signals a more serious problem. Here’s what you need to know.
An injection site reaction is your body’s local response to the needle itself, the fluid injected, or both. Common features include:
These symptoms usually develop within hours and improve over a few days. The vast majority of reactions are benign and reflect normal inflammation as your body absorbs the injected substance.
In most cases, you can expect:
If your symptoms match the above and are getting better each day, you’re probably experiencing a normal injection site reaction.
While most reactions are harmless, some signs mean it’s time to pay attention and possibly seek medical care:
If you notice any of the above—or if something simply doesn’t feel right—trust your instincts.
For typical soreness, redness, and swelling, you can often find relief with simple steps:
Avoid vigorous exercise or tight clothing over the site until discomfort improves.
While you can’t eliminate all post-injection soreness, these tips may help:
Even when symptoms are mild, you may have questions or want reassurance. If you’re unsure whether your injection site reaction is normal… you might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Always contact a healthcare provider right away if you experience:
And remember: if something could be life threatening or serious, speak to a doctor or call your local emergency number immediately.
Understanding what’s normal and when to worry helps you stay calm and take the right steps. Most injection site reactions resolve quickly with little intervention—but knowing the warning signs ensures you get prompt care if something more serious arises.
(References)
* Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4. PMID: 28478972.
* Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S28-S36. doi: 10.1016/j.jaad.2017.12.022. PMID: 29471919.
* Seegräber M, Srour J, Walter A, Knop M, Wollenberg A. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018 May;11(5):467-474. doi: 10.1080/17512433.2018.1449642. Epub 2018 Mar 20. PMID: 29557246.
* Zayed Y, Kheiri B, Banifadel M, Hicks M, Aburahma A, Hamid K, Bachuwa G, Chandran A. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. J Asthma. 2019 Oct;56(10):1110-1119. doi: 10.1080/02770903.2018.1520865. Epub 2018 Oct 1. PMID: 30273510.
* Gülsen A, Wedi B, Jappe U. Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events. Allergo J. 2020;29(4):32-61. doi: 10.1007/s15007-020-2550-1. Epub 2020 Jun 24. PMID: 32546899; PMCID: PMC7289641.
* Patel B, Priefer R. Infections associated with diabetic-care devices. Diabetes Metab Syndr. 2021 Mar-Apr;15(2):519-524. doi: 10.1016/j.dsx.2021.02.023. Epub 2021 Feb 19. PMID: 33668001.
* Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, Prajapati VH, Lio P, Hu X, Wu T, Liu J, Ladizinski B, Chu AD, Eyerich K. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2021 Sep 1;157(9):1047-1055. doi: 10.1001/jamadermatol.2021.3023. PMID: 34347860; PMCID: PMC8340015.
* Kyriazidis I, Spyropoulou GA, Zambacos G, Tagka A, Rakhorst HA, Gasteratos K, Berner JE, Mandrekas A. Adverse Events Associated with Hyaluronic Acid Filler Injection for Non-surgical Facial Aesthetics: A Systematic Review of High Level of Evidence Studies. Aesthetic Plast Surg. 2024 Feb;48(4):719-741. doi: 10.1007/s00266-023-03465-1. Epub 2023 Aug 10. PMID: 37563436.
* van Vollenhoven RF, Wang L, Merrill JT, Liu Y, Bao C, Li F, Hu J, Huang C, Zhao J, Huang C, Mo H, Wei W, Lu F, Li J, Zhao D, Wang W, Li L, Zuraw Q, Wang X, Wang X, Fang J, Zhang F, 18C010 Trial Investigators. A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus. N Engl J Med. 2025 Oct 16;393(15):1475-1485. doi: 10.1056/NEJMoa2414719. PMID: 41092329.
* Lebwohl M, Blauvelt A, Kartman CE, Leatherwood C, Gordon KB, Sattar N, Puig L, Merola JF, Siu K, Wang R, Sun L, Leung A, Somani N, Rueda MJ, Cardoso A, Genovese MC, Armstrong AW, Strober B. Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial. JAMA Dermatol. 2026 Jul 1;162(7):709-719. doi: 10.1001/jamadermatol.2026.1753. PMID: 42139049; PMCID: PMC13179568.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.